Advertisement

Clinical Pharmacokinetics

, Volume 10, Issue 5, pp 404–426 | Cite as

Drug Therapy in Patients Undergoing Peritoneal Dialysis

Clinical Pharmacokinetic Considerations
  • Thomas W. Paton
  • William R. Cornish
  • M. Arifie Manuel
  • Brian G. Hardy
Review Article

Summary

Peritoneal dialysis has become an accepted treatment modality for end-stage renal disease. The introduction of continuous ambulatory peritoneal dialysis (CAPD) has further popularised this technique. The need for adjustment of drug dosage in patients with endstage renal disease and the need for supplemental dosages following haemodialysis are well recognised. Little documentation exists concerning the need for supplemental drug dosage in patients on peritoneal dialysis. Knowledge of the influence of peritoneal dialysis on the elimination of specific drugs is essential to the rational design of dosage regimens in patients undergoing this dialysis technique.

This review addresses the clinical pharmacokinetic aspects of drug therapy in patients undergoing peritoneal dialysis and considers: (1) the efficiency of the peritoneal membrane as a dialysing membrane; (2) the effects of peritoneal dialysis on the pharmacokinetics of drugs; (3) the pharmacokinetic models and estimation methods for peritoneal dialysis clearance and the effects of peritoneal dialysis on drug elimination; (4) the influence of the pharmacokinetic parameters of drugs on drug dialysability; and (5) the application of pharmacokinetic principles to the adjustment of drug dosage regimens in peritoneal dialysis patients. Data on drugs which have been studied in peritoneal dialysis are tabulated with inclusion of pharmacokinetic and dialysability information.

Keywords

Peritoneal Dialysis Tobramycin Cephalexin Continuous Ambulatory Peritoneal Dialysis Total Body Clearance 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Ackermann, G.L.; Doherty, J.E. and Flanigan, W.J.: Peritoneal dialysis and hemodialysis of tritiated digoxin. Annals of Internal Medicine 67: 718–723 (1967).Google Scholar
  2. Ahem, M.J.; Finkelstein, F.O. and Andriote, V.T.: Pharmacokinetics of cefamandole in patients with renal failure. Antimicrobial Agents and Chemotherapy 11: 248–250 (1976).Google Scholar
  3. Alexander, D.; Gambertoglio, J.; Barriere, S.; Warnock, D. and Schoenfeld, P.: Cefotaxime pharmacokinetics during continuous ambulatory peritoneal dialysis. Clinical Pharmacology and Therapeutics 35: 225 (1984).Google Scholar
  4. Atkins, R.C.; Mion, C.; Despaux, E.; Van-Hai, N.; Julien, C. and Mion, H.: Peritoneal transfer of kanamycin and its use in peritoneal dialysis. Kidney International 3: 391–396 (1973).PubMedCrossRefGoogle Scholar
  5. Babb, A.L.; Johansen, P.J.; Strand, J.M.; Tenckoff, H. and Scribner, B.H.: Bi-directional permeability of the human peritoneum to middle molecules. Proceedings of the European Dialysis Transplant Association 10: 247–262 (1973).Google Scholar
  6. Bennett, W.M.; Aronoff, G.R.; Morrison, G.; Golper, T.A.; Pulliam, J.; Wolfson, M. and Singer, I.: Drug prescribing in renal failure: Dosing guidelines for adults. American Journal of Kidney Diseases 3: 155–193 (1983).PubMedGoogle Scholar
  7. Blumenkrantz, M.J.; Gahl, G.M.; Kupple, J.D.; Kamdar, A.V.; Jines, M.R.; Kessel, M. and Coburn, J.W.: Protein losses during peritoneal dialysis. Kidney International 19: 593–602 (1981).PubMedCrossRefGoogle Scholar
  8. Blye, E.; Lorch, J. and Cortell, S.: Extracorporeal therapy in the treatment of intoxication. American Journal of Kidney Diseases 3: 321–338 (1984).PubMedGoogle Scholar
  9. Boen, S.T.: Kinetics of peritoneal dialysis. A comparison with the artificial kidney. Medicine 40: 243–287 (1961).CrossRefGoogle Scholar
  10. Boen, S.T.: Peritoneal Dialysis in Clinical Medicine (Charles Thomas, Springfield, Illinois 1964).Google Scholar
  11. Bolton, N.D.; Gerig, J.S.; Scheid, W.M.; Swabb, E.A. and Bolton, W.K.: Peritoneal transfer of aztreonam in patients during continuous ambulatory peritoneal dialysis. Kidney International 25: 255 (1984).Google Scholar
  12. Brown, G.S.; Lohr, T.O.; Mayor, G.H.; Freitag, J.J.; Sanchez, T.V. and Prasad, J.M.: Peritoneal clearance of theophylline. American Journal of Kidney Diseases 1: 24–26 (1981).PubMedGoogle Scholar
  13. Bruns, R.R. and Palade, G.E.: Studies on blood capillaries. II. Transport of ferritin molecules across the wall of muscle capillaries. Journal of Cell Biology 37: 277–299 (1968).PubMedCrossRefGoogle Scholar
  14. Bunke, C; Aronoff, G.; Brier, M.; Sloan, R. and Luft, F.: Pharmacokinetics of vancomycin in continuous ambulatory peritoneal dialysis. Clinical Pharmacology and Therapeutics 33: 263 (1982).Google Scholar
  15. Bunke, C.M.; Aronoff, G.R.; Brier, M.E.; Sloan, R.S. and Luft, F.C.: Cefazolin and cephalexin kinetics in continuous ambulatory peritoneal dialysis. Clinical Pharmacology and Therapeutics 33: 66–72 (1983a).PubMedCrossRefGoogle Scholar
  16. Bunke, C.M.; Aronoff, G.R.; Brier, M.E.; Sloan, R.S. and Luft, F.C.: Tobramycin kinetics during continuous ambulatory peritoneal dialysis. Clinical Pharmacology and Therapeutics 34: 110–116 (1983b).PubMedCrossRefGoogle Scholar
  17. Bunke, C.M.; Aronoff, G.R.; Brier, M.E.; Sloan, R.S. and Luft, F.C.: Vancomycin kinetics during continuous ambulatory peritoneal dialysis. Clinical Pharmacology and Therapeutics 34: 631–637 (1983c).PubMedCrossRefGoogle Scholar
  18. Burgess, E.D. and Blair, A.D.: Pharmacokinetics of ceftizoxime in patients undergoing continuous ambulatory peritoneal dialysis. Antimicrobial Agents and Chemotherapy 24: 237–239 (1983).PubMedCrossRefGoogle Scholar
  19. Bush, A.; Holt, J.E.; Sankey, M.G.; Kaye, G.M. and Gabriel, R.: Penetration of metronidazole into continuous ambulatory peritoneal dialysate. Peritoneal Dialysis Bulletin 3: 176–177 (1983).Google Scholar
  20. Cassey, J.G.; Clark, D.A.; Merrick, P. and Jones, B.: Pharmacokinetics of metronidazole in patients undergoing peritoneal dialysis. Antimicrobial Agents and Chemotherapy 24: 950–951 (1983).PubMedCrossRefGoogle Scholar
  21. Chapman, J.R. and Warnock, D.W.: Ketoconazole and fungal CAPD peritonitis. Lancet 2: 510–511 (1983).PubMedCrossRefGoogle Scholar
  22. Chin, T.W.F.; Pancorbo, S. and Comty, C.: Quinidine pharmacokinetics in continuous ambulatory peritoneal dialysis. Clinical and Experimental Dialysis and Apheresis 5: 391–397 (1981).PubMedGoogle Scholar
  23. Comstock, T.J.; Straughn, A.B.; Kraus, A.P.; Meyer, M.C.; Finn, A.L. and Chubb, J.M.: Ceftazidime pharmacokinetics during continuous ambulatory peritoneal dialysis (CAPD) and intermittent peritoneal dialysis (IPD). Drag Intelligence and Clinical Pharmacy 17: 453 (1983).Google Scholar
  24. De Paepe, M.; Belpaire, F. and Bogaerts, Y.: Pharmacokinetics of digoxin in C.A.P.D. Clinical and Experimental Dialysis and Apheresis 6: 65–73 (1982).PubMedGoogle Scholar
  25. De Paepe, M.; Lameire, N.; Belpaire, F. and Bogaerts, Y.: Peritoneal pharmacokinetics of gentamicin in man. Clinical Nephrology 19: 107–109 (1983).PubMedGoogle Scholar
  26. De Paoli Vitali, E.; Casol, C.; Tessarin, C.; Tisoni, G.F. and Cavogna, R.: Pharmacokinetics of digoxin in CAPD; in Gahl et al. (Eds) Advances in Peritoneal Dialysis; Proceedings of the Second International Symposium on Peritoneal Dialysis, pp. 85–87 (Excerpta Medica, Amsterdam 1981).Google Scholar
  27. Drew, P.J.T.; Casewell, M.W.; Houang, E.T.; Simpson, C.N. and Marsh, F.P.: Cephalexin for the oral treatment of CAPD peritonitis. Journal of Antimicrobial Chemotherapy 13: 153–159 (1984).PubMedCrossRefGoogle Scholar
  28. Dubois, E.F.: Clinical Calorimetry. XII. The metabolism of boys 12 and 13 years old compared with the metabolism at other ages. Archives of Internal Medicine 17: 863–871 (1916).Google Scholar
  29. Eastwood, J.B. and Curtis, J.R.: Carbenicillin administration in patients with severe renal failure. British Medica! Journal 1: 486–487 (1968).CrossRefGoogle Scholar
  30. Faller, B. and Marichal, J.-F.: Loss of ultrafiltration in continuous ambulatory peritoneal dialysis: A role for acetate. Peritoneal Dialysis Bulletin 4: 10–13 (1984).Google Scholar
  31. Fish, S.S.; Pancorbo, S. and Berkseth, R.: Pharmacokinetics of epsilon-aminocaproic acid during peritoneal dialysis. Journal of Neurosurgery 54: 736–739 (1981).PubMedCrossRefGoogle Scholar
  32. Garcia, M.J.; Dominguez-Gil, A.; Tabanero, J.M. and Tomero, JA.: Pharmacokinetics of cefoxitin in patients with normal or impaired renal function. European Journal of Clinical Pharmacy 16: 119–124 (1979).CrossRefGoogle Scholar
  33. Gary, N.E.: Peritoneal clearance and removal of gentamicin. Journal of Infectious Diseases 124 (Suppl.): S96–S97 (1971).PubMedCrossRefGoogle Scholar
  34. Gloor, H.J.; Moore, H. and Nolph, K.D.: The peritoneal handling of digoxin during CAPD. Peritoneal Dialysis Bulletin 2: 13–16 (1982).Google Scholar
  35. Gokal, R.; McHugh, M.; Eddis, H.A.; Elliot, R.W.; Wilkinson, R.; Dewar, J.; Ward, M.K. and Kerr, D.N.S.: Comparison and integration of IPD, CAPD and HD in Newcastle-upon-Tyne and for UK; in Atkins et al. (Eds) Peritoneal Dialysis, pp.404–413 (Churchill Livingstone, Edinburgh 1981).Google Scholar
  36. Goodwin, N.J. and Friedman, E.A.: The effect of renal impairment, peritoneal dialysis and hemodialysis on serum sodium colistimethate levels. Annals of Internal Medicine 68: 984–994 (1968).PubMedGoogle Scholar
  37. Greaves, W.C.; Kreeft, J.H.; Ogilvie, R.I. and Richards, G.K.: Cefoxitin disposition during peritoneal dialysis. Antimicrobial Agents and Chemotherapy 19: 253–255 (1981).PubMedCrossRefGoogle Scholar
  38. Greenberg, P.A. and Sanford, J.P.: Removal and absorption of antibiotics in patients with renal failure undergoing peritoneal dialysis. Annals of Internal Medicine 66: 465–478 (1967).PubMedGoogle Scholar
  39. Gross, M.L.; Somani, P.; Ribner, B.S.; Raeader, R.; Freimer, E.H. and Higgins, J.T.: Ceftizoxime elimination kinetics in continuous ambulatory peritoneal dialysis. Clinical Pharmacology and Therapeutics 34: 673–680 (1983).PubMedCrossRefGoogle Scholar
  40. Guay, D.R.; Meatherall, R.C.; Baxter, H.; Jacyk, W.R. and Penner, A.: Pharmacokinetics of metronidazole in patients undergoing continuous ambulatory peritoneal dialysis. Antimicrobial Agents and Chemotherapy 25: 306–310 (1984).PubMedCrossRefGoogle Scholar
  41. Hall, K.; Meatherall, A.; Krahn, J.; Penner, B. and Rabson, J.L.: Clearance of quinidine during peritoneal dialysis. American Heart Journal 104: 646–647 (1982).PubMedCrossRefGoogle Scholar
  42. Halstenson, C.E.; Matzke, G.R. and Comty, C.: Intraperitoneal administration of tobramycin during continuous ambulatory peritoneal dialysis. Kidney International 25: 256 (1984).Google Scholar
  43. Hamann, S.R.; Oeltgen, P.R.; Shank, W.A.; Blouin, R.A. and Nalarajan, L.: Evaluation of gentamicin pharmacokinetics during peritoneal dialysis. Therapeutic Drug Monitoring 4: 297–300 (1982).PubMedCrossRefGoogle Scholar
  44. Harford, A.M.; Sica, D.A.; Tartaglione, T.; Polk, R.E.; Dalton, H.P. and Poynor, W.J.: Vancomycin pharmacokinetics in continuous ambulatory peritoneal dialysis patients with peritonitis. Kidney International 25: 257 (1984).Google Scholar
  45. Harrington, J.T.: Chronic continuous peritoneal dialysis. New England Journal of Medicine 306: 670–671 (1982).PubMedCrossRefGoogle Scholar
  46. Jaffe, G.; Meyers, B.R. and Hirschmann, S.Z.: Pharmacokinetics of tobramycin in patients with stable renal impairment, patients undergoing peritoneal dialysis, and patients on chronic hemodialysis. Antimicrobial Agents and Chemotherapy 5: 611–616 (1974).PubMedCrossRefGoogle Scholar
  47. Jones, R.H.; Cundy, T.; Bullock, R.; Brown, C.W.; Dafton, J.; Majer, R.; Parsons, V. and Bridgman, K.M.: Concentrations of amoxycillin in serum and dialysate of uraemic patients undergoing peritoneal dialysis. Journal of Infection 1: 235–242 (1979).CrossRefGoogle Scholar
  48. Jusko, W.J.; Baliah, T.; Kim, K.H.; Gerbracht, L.M. and Yaffe, S.J.: Pharmacokinetics of gentamicin during peritoneal dialysis in children. Kidney International 9: 430–438 (1976).PubMedCrossRefGoogle Scholar
  49. Kampf, D.; Schurig, R.; Weihermuller, K. and Forster, D.: Effects of impaired renal function, hemodialysis, and peritoneal dialysis on the pharmacokinetics of mezlocillin. Antimicrobial Agents and Chemotherapy 18: 81–87 (1980).PubMedCrossRefGoogle Scholar
  50. Kaye, D.; Wenger, N. and Agarwal, B.: Pharmacology of intraperitoneal cefazolin in patients undergoing peritoneal dialysis. Antimicrobial Agents and Chemotherapy 14: 318–321 (1978).PubMedCrossRefGoogle Scholar
  51. Keller, E.; Jansen, A.; Pelz, K.; Hoppe-Seyler, G. and Schollmeyer, P.: Intraperitoneal and intravenous cefoperazone kinetics during continuous ambulatory peritoneal dialysis. Clinical Pharmacology and Therapeutics 35: 208–213 (1984).PubMedCrossRefGoogle Scholar
  52. Keller, F.; Offermann, G. and Lode, H.: Supplementary dose after hemodialysis. Nephron 30: 220–227 (1982).PubMedCrossRefGoogle Scholar
  53. Kogan, F.J.; Sampliner, R.E.; Mayersohn, M.; Kazama, R.M.; Perrier, D.; Jones, W. and Michael, U.F.: Cimetidine disposition in patients undergoing continuous ambulatory peritoneal dialysis. Journal of Clinical Pharmacology 23: 252–256 (1983).PubMedGoogle Scholar
  54. Kosmidis, J.; Stathakis, C.; Anyfantis, A. and Daikos, G.K.: Cefuroxime in renal insufficiency: Therapeutic results in various infections and pharmacokinetics including the effects of dialysis. Proceedings of the Royal Society of Medicine 70 (Suppl. 9): 139–143 (1977).PubMedGoogle Scholar
  55. Krogstad, D.J.; Moellering, R.C. and Greenblatt, D.J.: Single-dose kinetics of intravenous vancomycin. Journal of Clinical Pharmacology 20: 197–201 (1980).PubMedGoogle Scholar
  56. Krothapalli, R.K.; Senekjian, H.O. and Ayus, J.C.: Efficacy of intravenous vancomycin in the treatment of Gram-positive peritonitis in long-term peritoneal dialysis. American Journal of Medicine 75: 345–348 (1983).PubMedCrossRefGoogle Scholar
  57. LaGreca, G.; Biasioli, S.; Chairamonte, S.; Fabris, A.; Feriani, M.; Pisani, E.; Ronco, C. and Xerri, L.: Pharmacokinetics of intravenous and intraperitoneal cefuroxime during peritoneal dialysis. International Journal of Clinical Pharmacology, Therapy and Toxicology 20: 92–94 (1982).Google Scholar
  58. Lee, C.C. and Marbury, T.C.: Drug therapy in patients undergoing haemodialysis: Clinical pharmacokinetic considerations. Clinical Pharmacokinetics 9: 42–66 (1984).PubMedCrossRefGoogle Scholar
  59. Lee, C.C.; Peterson, J.C. and Marbury, T.C.: Comparative pharmacokinetics of theophylline in peritoneal dialysis and hemodialysis. Journal of Clinical Pharmacology 23: 274–280 (1983).PubMedGoogle Scholar
  60. Levison, M.E.; Levison, S.P.; Ries, K. and Kaye, D.: Pharmacology of cefazolin in patients with normal and abnormal renal function. Journal of Infectious Diseases 128 (Suppl.): S354–S357 (1973).PubMedCrossRefGoogle Scholar
  61. Local, F.K.; Munro, A.J.; Kerr, D.N.S. and Sussman, M.: Pharmacokinetics of intravenous and intraperitoneal cefuroxime in patients undergoing peritoneal dialysis. Clinical Nephrology 16: 40–43 (1981).PubMedGoogle Scholar
  62. Luthy, R.; Blaser, J.; Bonetli, A.; Hanspeter, S.; Wise, R. and Siegenthaler, W.: Comparative multiple-dose pharmacokinetics of cefotaxime, moxalactam and ceftazidime. Antimicrobial Agents and Chemotherapy 29: 567–757 (1981).CrossRefGoogle Scholar
  63. Madhavan, T.; Yaremchuk, K.; Levin, N.; Fisher, E.; Cox, F.; Burch, K.; Haas, E.; Pohlod, D. and Quinn, E.L.: Effects of renal failure and dialysis on cefazolin pharmacokinetics. Antimicrobial Agents and Chemotherapy 8: 63–66 (1975).PubMedCrossRefGoogle Scholar
  64. Madhavan, T.; Yaremchuk, K.; Levin, N.; Puhlod, K.; Burch, K.; Fisher, E.; Cox, F. and Quinn, E.L.: Effect of renal failure and dialysis on the serum concentration of the aminoglycoside amikacin. Antimicrobial Agents and Chemotherapy 10: 464–466 (1976).PubMedCrossRefGoogle Scholar
  65. Magera, B.E.; Arroyo, J.C.; Rosansky, S.J. and Postic, A.: Vancomycin pharmacokinetics in patients with peritonitis on peritoneal dialysis. Antimicrobial Agents and Chemotherapy 23: 710–714 (1983).PubMedCrossRefGoogle Scholar
  66. Malacoff, R.F.; Finkelstein, F.O. and Andriole, V.T.: Effect of peritoneal dialysis on serum levels of tobramycin and clindamycin. Antimicrobial Agents and Chemotherapy 8: 574–580 (1975).PubMedCrossRefGoogle Scholar
  67. Manuel, M.A.; Paton, T.W. and Cornish, W.R.: Drugs and peritoneal dialysis. Peritoneal Dialysis Bulletin 3: 117–125 (1983).Google Scholar
  68. Manuel, M.A. and The University of Toronto Collaborative Dialysis Group: Failure of ultrafiltration in patients on CAPD. Peritoneal Dialysis Bulletin 3 (Suppl. 3): S38–S40 (1983).Google Scholar
  69. Matzke, G.R.; Halstenson, C.E.; Blevins, R.B. and Salem, N.G.: Trimethoprim-sulfamethoxazole pharmacokinetics during continuous ambulatory peritoneal dialysis. Clinical Pharmacology and Therapeutics 33: 235 (1983a).Google Scholar
  70. Matzke, G.R.; Halstenson, C.E.; Blevins, R.B. and Salem, N.G.: Pharmacokinetics of vancomycin during continuous ambulatory peritoneal dialysis. Clinical Pharmacology and Therapeutics 23: 236 (1983b).Google Scholar
  71. Matzke, G.R.; Salem, N.; Bockbrader, H. and Blevins, R.: The effect of peritoneal dialysis on the pharmacokinetics of amikacin. Proceedings of the Dialysis Transplant Forum 10: 302–304 (1980).Google Scholar
  72. Meyers, B.R. and Hirschmann, S.Z.: Pharmacokinetics of cefamandole in patients with renal failure. Antimicrobial Agents and Chemotherapy 11: 248–250 (1977).PubMedCrossRefGoogle Scholar
  73. Miller, F.N.: The peritoneal microcirculation; in Nolph (Ed.) Peritoneal Dialysis, pp. 42–78 (Martinus Nijhoff, The Hague 1981).Google Scholar
  74. Moellering, R.C.; Krogstad, D.J. and Greenblatt, D.J.: Vancomycin therapy in patients with impaired renal function: A nomogram for dosage. Annals of Internal Medicine 94: 343–346 (1981).PubMedGoogle Scholar
  75. Munch, R.; Steurer, J.; Luthy, R.; Siegenthaler, W. and Kuhlmann, U.: Serum and dialysate concentrations of intraperitoneal cephalothin in patients undergoing continuous ambulatory peritoneal dialysis. Clinical Nephrology 20: 40–43 (1983).PubMedGoogle Scholar
  76. Nielsen, H.E.; Sorensen, I. and Hansen, H.E.: Peritoneal transport of vancomycin during peritoneal dialysis. Nephron 24: 274–277 (1979).PubMedCrossRefGoogle Scholar
  77. Nolph, KD.: Peritoneal clearances. Journal of Laboratory and Clinical Medicine 94: 519–525 (1979).PubMedGoogle Scholar
  78. Nolph, K.D.; Miller, F.N.; Popovich, R.P. and Sorkin, M.I.: An hypothesis to explain the ultrafiltration characteristics of peritoneal dialysis. Kidney International 20: 543–548 (1981).PubMedCrossRefGoogle Scholar
  79. Nolph, K.D.; Miller, F.N.; Rubin, J. and Popovich, R.: New directions in peritoneal dialysis concepts and applications. Kidney International 18 (Suppl.): S111–S116 (1980).Google Scholar
  80. Nolph, K.D. and Sorkin, M.I.: The peritoneal dialysis system; in Nolph (Ed.) Peritoneal Dialysis, pp. 21–41 (Martinus Nijhoff, The Hague 1981).Google Scholar
  81. Odar-Cederlöf, I. and Borgå, O.: Kinetics of diphenylhydantoin in uremic patients: Consequences of decreased plasma protein binding. European Journal of Clinical Pharmacology 7: 31–37 (1974).PubMedCrossRefGoogle Scholar
  82. Ohkawa, M.; Okasho, A.; Sugata, T. and Kuroda, K.: Elimination kinetics of ceftizoxime in humans with and without renal insufficiency. Antimicrobial Agents and Chemotherapy 22: 308–311 (1982).PubMedCrossRefGoogle Scholar
  83. Pancorbo, S. and Comty, C.: Digoxin pharmacokinetics in continuous peritoneal dialysis. Annals of Internal Medicine 93: 639 (1980).PubMedGoogle Scholar
  84. Pancorbo, S. and Comty, C.: Pharmacokinetics of gentamicin in patients undergoing continuous ambulatory peritoneal dialysis. Antimicrobial Agents and Chemotherapy 19: 605–607 (1981).PubMedCrossRefGoogle Scholar
  85. Pancorbo, S. and Comty, C.: Peritoneal transport of vancomycin in 4 patients undergoing continuous ambulatory peritoneal dialysis. Nephron 31: 37–39 (1982).PubMedCrossRefGoogle Scholar
  86. Pancorbo, S. and Comty, C.: Pharmacokinetics of cefamandole in patients undergoing continuous ambulatory peritoneal dialysis. Peritoneal Dialysis Bulletin 3: 135–137 (1983).Google Scholar
  87. Pappenheimer, J.R.: Passage of molecules through capillary walls. Physiological Reviews 33: 387–423 (1953).PubMedGoogle Scholar
  88. Pappenheimer, J.R.: Über die Permeabilität der Glomerulomembranen in der Niere. Klinische Wochenschrift 33: 362–365 (1955).PubMedCrossRefGoogle Scholar
  89. Parry, M.F. and Neu, H.C.: Pharmacokinetics of ticarcillin in patients with abnormal renal function. Journal of Infectious Diseases 133: 46–49 (1976).PubMedCrossRefGoogle Scholar
  90. Paton, T.W.; Manuel, M.A.; Cohen, L.B. and Walker, S.E.: The disposition of cefazolin and tobramycin following intraperitoneal administration in patients on continuous ambulatory peritoneal dialysis. Peritoneal Dialysis Bulletin 3: 73–76 (1983).Google Scholar
  91. Paton, T.W.; Manuel, M.A. and Walker, S.E.: Cimetidine disposition in patients on continuous ambulatory peritoneal dialysis. Peritoneal Dialysis Bulletin 2: 73–76 (1982a).Google Scholar
  92. Paton, T.W.; Manuel, M.A. and Walker, S.E.: Tobramycin disposition in patients on continuous ambulatory peritoneal dialysis. Peritoneal Dialysis Bulletin 2: 179–181 (1982b).Google Scholar
  93. Peters, U.; Risler, T. and Grabensee, B.: Pharmacokinetics of digitoxin with end-stage renal failure treated with continuous ambulatory peritoneal dialysis. Kidney International 20: 159 (1981).Google Scholar
  94. Pizzella, K.M.; Moore, M.C.; Schultz, R.W.; Walshe, J. and Schentag, J.J.: Removal of Cimetidine by peritoneal dialysis, hemodialysis and charcoal hemoperfusion. Therapeutic Drug Monitoring 2: 273–281 (1980).PubMedCrossRefGoogle Scholar
  95. Popovich, R.P. and Moncrief, J.W.: Kinetic modeling of peritoneal transport. Contributions to Nephrology 17: 59–72 (1979).PubMedGoogle Scholar
  96. Ramos, E.; Adir, J.A.; Shen, Y.L.; Leslie, J.; Atkins, J. and Sadler, J.H.: Pharmacokinetics of tobramycin in patients undergoing peritoneal dialysis. Kidney International 16: 896 (1979).Google Scholar
  97. Regeur, L.; Colding, H.; Jensen, H. and Kampmann, J.P.: Pharmacokinetics of amikacin during hemodialysis and peritoneal dialysis. Antimicrobial Agents and Chemotherapy 11: 214–218 (1977).PubMedCrossRefGoogle Scholar
  98. Reidenberg, M.M.: The binding of drugs to plasma proteins and the interpretation of measurements of plasma concentrations of drugs in patients with poor renal function. American Journal of Medicine 62: 466–469 (1977a).PubMedCrossRefGoogle Scholar
  99. Reidenberg, M.M.: The biotransformation of drugs in renal failure. American Journal of Medicine 62: 482–485 (1977b).PubMedCrossRefGoogle Scholar
  100. Reinarz, J.A. and Mcintosh, D.A.: Lincomycin excretion in patients with normal renal function, severe azotemia, and with hemodialysis and peritoneal dialysis. Antimicrobial Agents and Chemotherapy 5: 232–238 (1965).PubMedGoogle Scholar
  101. Renkin, E.M.: Relation of capillary morphology to transport of fluid and large molecules. Acta Physiologica Scandinavica 106 (Suppl. 463): 81–91 (1979).Google Scholar
  102. Reudy, J.: The effects of peritoneal dialysis on the physiological disposition of oxacillin, ampicillin, and tetracycline in patients with renal disease. Canadian Medical Association Journal 94: 257–261 (1966).Google Scholar
  103. Reuning, R.H.; Sams, R.A. and Notari, R.E.: Role of pharmacokinetics in drug dosage adjustment: Pharmacologic effect, kinetics and apparent volume of distribution of digoxin. Journal of Clinical Pharmacology 13: 127–141 (1973).Google Scholar
  104. Risler, T.; Peters, U.; Pablick, J.; Grabensee, B. and Krokou, J.: Pharmacokinetics of digoxin and digitoxin in patients on continuous ambulatory peritoneal dialysis; in Gahl et al. (Eds) Advances in Peritoneal Dialysis; Proceedings of the Second International Symposium on Peritoneal Dialysis, pp. 88–89 (Excerpta Medica, Amsterdam 1981).Google Scholar
  105. Sargent, J.A. and Gotch, F.A.: Mathematic modeling of dialysis therapy. Kidney International 18 (Suppl. 10): S2–S10 (1980).Google Scholar
  106. Schurig, R.; Kampf, D.; Spieber, W.; Weihermuller, K. and Becker, H.: Cefotaxime pharmacokinetics in peritoneal dialysis; in Gahl et al. (Eds) Advances in Peritoneal Dialysis; Proceedings of the Second International Symposium on Peritoneal Dialysis, pp. 96–98 (Excerpta Medica, Amsterdam 1981).Google Scholar
  107. Singlas, E.; Boutron, H.F.; Merdjan, H.; Brocard, J.F.; Pocheville, M. and Fries, D.: Moxalactam kinetics during chronic ambulatory peritoneal dialysis. Clinical Pharmacology and Therapeutics 34: 403–407 (1983).PubMedCrossRefGoogle Scholar
  108. Singlas, E.; Colin, J.N.; Rottembourg, J.; Meesen, J.P.; de Martin, A. and Simon, P.: Pharmacokinetics of sulfamethoxazole-trimethoprim combination during chronic peritoneal dialysis: Effects of peritonitis. European Journal of Clinical Pharmacology 21: 409–415 (1982).PubMedCrossRefGoogle Scholar
  109. Smithivas, I.; Hyams, P.J.; Matalon, R.; Simberkoff, M.S. and Rahahl, J.J.: The use of gentamicin in peritoneal dialysis. I. Pharmacologic results. Journal of Infectious Diseases 124 (Suppl.): S77–S83 (1971).PubMedCrossRefGoogle Scholar
  110. Somani, P.; Shapiro, R.S.; Stockard, H. and Higgins, J.T.: Unidirectional absorption of gentamicin from the peritoneum during continuous ambulatory peritoneal dialysis. Clinical Pharmacology and Therapeutics 32: 113–121 (1982).PubMedCrossRefGoogle Scholar
  111. Stephens, N.M.; Kronfol, N.O.; Kline, B.J. and Polk, R.E.: Peritoneal absorption of moxalactam. Antimicrobial Agents and Chemotherapy 24: 39–41 (1983).PubMedCrossRefGoogle Scholar
  112. Tenckhoff, H.; Ward, G. and Böen, S.T.: The influence of dialy-sate volume and flow rate on peritoneal clearance. Proceedings of the European Dialysis and Transplant Association 2: 113–117 (1965).Google Scholar
  113. Ti, T.Y.; Fortin, L.; Kreeft, J.H.; East, D.S.; Ogilvie, R.I. and Somerville, P.J.: Kinetic disposition of intravenous ceftriaxone in normal subjects and patients with renal failure on hemodialysis or peritoneal dialysis. Antimicrobial Agents and Chemotherapy 25: 83–87 (1984).PubMedCrossRefGoogle Scholar
  114. Tourkantonis, A. and Nicolaidis, P.: Pharmacokinetics of ceftazidime in patients undergoing peritoneal dialysis. Journal of Antimicrobial Chemotherapy 12 (Suppl. A): 263–267 (1983).PubMedCrossRefGoogle Scholar
  115. Twardowski, Z.; Ksiazek, A.; Majdan, M.; Janicka, L.; Bochenska-Nowacka, E.; Sokolowska, G.; Gutka, A. and Zbikowska, A.: Kinetics of continuous ambulatory peritoneal dialysis (CAPD) with four exchanges per day. Clinical Nephrology 15: 119–130 (1981).PubMedGoogle Scholar
  116. Vaziri, N.D.; Ness, R.L. and Barton, C.H.: Peritoneal dialysis clearance of Cimetidine. American Journal of Gastroenterology 71: 572–576 (1979).PubMedGoogle Scholar
  117. Wade, O.L.; Combes, B.; Childs, A.W.; Wheelers, H.O.; Counard, A. and Bradley, S.E.: The effect of exercise on splanchnic blood flow. Clinical Science 15: 457–463 (1956).PubMedGoogle Scholar
  118. Whelton, A.; Stout, R.L. and Delgado, F.A.: Azlocillin kinetics during extracorporeal haemodialysis and peritoneal dialysis. Journal of Antimicrobial Chemotherapy 11 (Suppl. B): 89–95 (1983).PubMedCrossRefGoogle Scholar
  119. Williams, P.; Khanna, R.; Simpson, H. and Vas, S.I.: Tobramycin blood levels of CAPD patients during peritonitis. Peritoneal Dialysis Bulletin 2: 48 (1982).Google Scholar
  120. Wise, R.; Wright, N. and Wills, P.J.: Pharmacology of cefotaxime and its desacetyl metabolite in renal and hepatic disease. Antimicrobial Agents and Chemotherapy 19: 526–531 (1981).PubMedCrossRefGoogle Scholar
  121. Yamasaku, F.; Tsuchida, R. and Usuda, Y.: A study of the kinetics of cephalosporins in renal impairment. Journal of Postgraduate Medicine 46 (Suppl.): 57–59 (1970).Google Scholar
  122. Yonce, G.; Sica, D.; Small, R.; Harford, A. and Poynor, W.: Pharmacokinetics of procainamide in continuous ambulatory peritoneal dialysis (CAPD). Clinical Pharmacology and Therapeutics 35: 285 (1984).Google Scholar

Copyright information

© ADIS Press Limited 1985

Authors and Affiliations

  • Thomas W. Paton
    • 1
  • William R. Cornish
    • 1
  • M. Arifie Manuel
    • 1
  • Brian G. Hardy
    • 1
  1. 1.Departments of Pharmacy and MedicineSunnybrook Medical Centre and The University of TorontoTorontoCanada

Personalised recommendations